Burkholderia Infections - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Burkholderia Infections - Pipeline Review, H2 2016’, provides an overview of the Burkholderia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections

The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects

The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burkholderia Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burkholderia Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aridis Pharmaceuticals LLC

Arno Therapeutics Inc

Bavarian Nordic A/S

Emergent BioSolutions Inc

Eumedica SA

Grifols SA

Sarepta Therapeutics Inc

Soligenix Inc

Syntiron LLC

TGV-Laboratories

Vault ...

Aridis Pharmaceuticals LLC

Arno Therapeutics Inc

Bavarian Nordic A/S

Emergent BioSolutions Inc

Eumedica SA

Grifols SA

Sarepta Therapeutics Inc

Soligenix Inc

Syntiron LLC

TGV-Laboratories

Vault Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Burkholderia Infections ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Burkholderia Infections Overview 8

Therapeutics Development 9

Pipeline Products for Burkholderia Infections - Overview 9

Pipeline Products for Burkholderia Infections - Comparative Analysis 10

Burkholderia Infections - Therapeutics under Development by Companies 11

Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes 12

Burkholderia Infections - Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Burkholderia Infections - Products under Development by Companies 16

Burkholderia Infections - Products under Investigation by Universities/Institutes 17

Burkholderia Infections - Companies Involved in Therapeutics Development 18

Aridis Pharmaceuticals LLC 18

Arno Therapeutics Inc 19

Bavarian Nordic A/S 20

Emergent BioSolutions Inc 21

Eumedica SA 22

Grifols SA 23

Sarepta Therapeutics Inc 24

Soligenix Inc 25

Syntiron LLC 26

TGV-Laboratories 27

Vault Pharma Inc 28

Burkholderia Infections - Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AR-13 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ARD-3100 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ARD-3150 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Burkholderia pseudomallei vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Burkholderia vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Burkholderia vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

dusquetide - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

EV-035 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

GC-072 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

melioidosis vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Mul-1867 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Panaecin - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

SGX-943 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecules for Infectious Diseases - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

temocillin - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

VPI-231 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Burkholderia Infections - Dormant Projects 68

Burkholderia Infections - Discontinued Products 69

Burkholderia Infections - Product Development Milestones 70

Featured News & Press Releases 70

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis 70

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 70

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072 71

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 72

Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development for Burkholderia Infections, H2 2016 9

Number of Products under Development for Burkholderia Infections - Comparative Analysis, ...

List of Tables

Number of Products under Development for Burkholderia Infections, H2 2016 9

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Comparative Analysis by Unknown Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Burkholderia Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 18

Burkholderia Infections - Pipeline by Arno Therapeutics Inc, H2 2016 19

Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H2 2016 20

Burkholderia Infections - Pipeline by Emergent BioSolutions Inc, H2 2016 21

Burkholderia Infections - Pipeline by Eumedica SA, H2 2016 22

Burkholderia Infections - Pipeline by Grifols SA, H2 2016 23

Burkholderia Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016 24

Burkholderia Infections - Pipeline by Soligenix Inc, H2 2016 25

Burkholderia Infections - Pipeline by Syntiron LLC, H2 2016 26

Burkholderia Infections - Pipeline by TGV-Laboratories, H2 2016 27

Burkholderia Infections - Pipeline by Vault Pharma Inc, H2 2016 28

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Stage and Target, H2 2016 31

Number of Products by Stage and Mechanism of Action, H2 2016 33

Number of Products by Stage and Route of Administration, H2 2016 35

Number of Products by Stage and Molecule Type, H2 2016 37

Burkholderia Infections - Dormant Projects, H2 2016 68

Burkholderia Infections - Discontinued Products, H2 2016 69

List of Figures

List of Figures

Number of Products under Development for Burkholderia Infections, H2 2016 9

Number of Products under Development for Burkholderia Infections - Comparative Analysis, ...

List of Figures

Number of Products under Development for Burkholderia Infections, H2 2016 9

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Targets, H2 2016 30

Number of Products by Stage and Targets, H2 2016 30

Number of Products by Mechanism of Actions, H2 2016 32

Number of Products by Stage and Mechanism of Actions, H2 2016 32

Number of Products by Routes of Administration, H2 2016 34

Number of Products by Stage and Routes of Administration, H2 2016 34

Number of Products by Molecule Types, H2 2016 36

Number of Products by Stage and Molecule Types, H2 2016 36

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports